cell and gene therapies

CAR-T: What’s next? Part 2

In my previous blog post, I suggested that the market size for gene-modified T-cell therapies would be roughly $9 Bn in 10 years, with a...

CAR-T: What’s next? Part 1

Over the last two months, several news events have brought CAR-T cells to widespread public attention, the most prominent of which is the...

Artificial intelligence in pharma, health care is at the crossroads of hype and reality

Low-end disruption coming to the Ultrasound market

Artificial intelligence in pharma, health care is at the crossroads of hype and reality

Low-end disruption coming to the Ultrasound market

CAR-T: What’s next? Part 2

CAR-T: What’s next? Part 1

Is Digital Health ever going to become mainstream?

Pharmacy Benefit Managers (PBMs): Bending the cost curve in the wrong direction